Table 1.
(Revised). Baseline characteristics by local treatment strategy for the MarketScan cohort*
| Lump+WBI (n = 17 550) |
Lump + Brachy (n = 2414) |
Lump alone (n = 2229) |
Mast alone (n = 6357) |
Mast+Recon (n = 11 624) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) |
| Age, y | ||||||||||
| <40 | 615 | 3.5 | 5 | .2 | 187 | 8.4 | 169 | 2.7 | 1221 | 10.5 |
| 40–49 | 4720 | 26.9 | 395 | 16.4 | 770 | 34.5 | 1221 | 19.2 | 4396 | 37.8 |
| 50–59 | 9096 | 51.8 | 1413 | 58.5 | 1009 | 45.3 | 3376 | 53.1 | 4870 | 41.9 |
| 60–64 | 3119 | 17.8 | 601 | 24.9 | 263 | 11.8 | 1591 | 25.0 | 1137 | 9.8 |
| Type of coverage | ||||||||||
| non-HMO | 14 430 | 82.2 | 2075 | 86.0 | 1829 | 82.1 | 5093 | 80.1 | 9419 | 81.0 |
| HMO | 3120 | 17.8 | 339 | 14.0 | 400 | 18.0 | 1264 | 19.9 | 2205 | 19.0 |
| Covered individual | ||||||||||
| Employee | 10 848 | 61.8 | 1524 | 63.1 | 1278 | 57.3 | 3726 | 58.6 | 6779 | 58.3 |
| Dependent | 6702 | 38.2 | 890 | 36.9 | 951 | 42.7 | 2631 | 41.4 | 4845 | 41.7 |
| Comorbidity | ||||||||||
| 0 | 15 860 | 90.4 | 2143 | 88.8 | 1993 | 89.4 | 5492 | 86.4 | 10 749 | 92.5 |
| 1 | 1458 | 8.3 | 230 | 9.5 | 187 | 8.4 | 707 | 11.1 | 757 | 6.5 |
| ≥2 | 232 | 1.3 | 41 | 1.7 | 49 | 2.2 | 158 | 2.5 | 118 | 1.0 |
| Year | ||||||||||
| 2000 | 271 | 1.5 | 4 | .2 | 110 | 4.9 | 244 | 3.8 | 226 | 1.9 |
| 2001 | 303 | 1.7 | 1 | .0 | 102 | 4.6 | 255 | 4.0 | 241 | 2.1 |
| 2002 | 338 | 1.9 | 9 | .4 | 140 | 6.3 | 397 | 6.3 | 328 | 2.8 |
| 2003 | 644 | 3.7 | 50 | 2.1 | 202 | 9.1 | 525 | 8.3 | 533 | 4.6 |
| 2004 | 847 | 4.8 | 65 | 2.7 | 207 | 9.3 | 459 | 7.2 | 602 | 5.2 |
| 2005 | 1167 | 6.7 | 94 | 3.9 | 236 | 10.6 | 530 | 8.3 | 755 | 6.5 |
| 2006 | 1255 | 7.2 | 184 | 7.6 | 211 | 9.5 | 541 | 8.5 | 823 | 7.1 |
| 2007 | 2005 | 11.4 | 332 | 13.8 | 216 | 9.7 | 696 | 11.0 | 1277 | 11.0 |
| 2008 | 1975 | 11.3 | 391 | 16.2 | 182 | 8.2 | 639 | 10.1 | 1327 | 11.4 |
| 2009 | 2904 | 16.6 | 436 | 18.1 | 260 | 11.7 | 725 | 11.4 | 1836 | 15.8 |
| 2010 | 3095 | 17.6 | 448 | 18.6 | 205 | 9.2 | 739 | 11.6 | 1907 | 16.4 |
| 2011 | 2746 | 15.7 | 400 | 16.6 | 158 | 7.1 | 607 | 9.6 | 1769 | 15.2 |
| Chemotherapy | ||||||||||
| No | 10 742 | 61.2 | 1946 | 80.6 | 1902 | 85.3 | 3557 | 56.0 | 7337 | 63.1 |
| Yes | 6808 | 38.8 | 468 | 19.4 | 327 | 14.7 | 2800 | 44.1 | 4287 | 36.9 |
| Trastuzumab | ||||||||||
| No | 16 454 | 93.8 | 2328 | 96.4 | 2199 | 98.7 | 5928 | 93.3 | 10 861 | 93.4 |
| Yes | 1096 | 6.3 | 86 | 3.6 | 30 | 1.4 | 429 | 6.8 | 763 | 6.6 |
| Axillary surgery | ||||||||||
| No | 3631 | 20.7 | 531 | 22.0 | 1503 | 67.4 | 684 | 10.8 | 1869 | 16.1 |
| Yes | 13 919 | 79.3 | 1883 | 78.0 | 726 | 32.6 | 5673 | 89.2 | 9755 | 83.9 |
| Bilateral mastectomy | ||||||||||
| No | 17 550 | 100 | 2414 | 100 | 2229 | 100 | 5701 | 89.7 | 8128 | 69.9 |
| Yes | 0 | 0 | 0 | 0 | 0 | 0 | 656 | 10.3 | 3496 | 30.1 |
| Node positive | ||||||||||
| No | 15 261 | 87.0 | 2356 | 97.6 | 2100 | 94.2 | 5185 | 81.6 | 10 174 | 87.5 |
| Yes | 2289 | 13.0 | 58 | 2.4 | 129 | 5.8 | 1172 | 18.4 | 1450 | 12.5 |
| Endocrine therapy | ||||||||||
| No | 7127 | 40.6 | 913 | 37.8 | 1641 | 73.6 | 3018 | 47.5 | 6313 | 54.3 |
| yes | 10 423 | 59.4 | 1501 | 62.2 | 588 | 26.4 | 3339 | 52.5 | 5311 | 45.7 |
*P value < .001 (chi-square) for all comparisons of treatment strategy by patient and treatment characteristics. Brachy = brachytherapy; HMO = Health Maintenance Organization; Lump = lumpectomy; Mast = mastectomy; WBI = whole breast irradiation.